OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

Rhea-AI Summary

OTC Markets Group (OTCQX: OTCM) announced that Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. The company has transitioned from its previous NASDAQ listing and commenced trading on the OTCQX under the symbol "VXRT" on July 8, 2025.

The OTCQX Market provides companies with cost-effective access to U.S. capital markets while maintaining high financial standards and corporate governance requirements. Vaxart's CEO Steven Lo emphasized the company's continued commitment to developing oral pill vaccines for public health advancement.

Positive

• Qualification for OTCQX trading indicates meeting high financial standards and corporate governance requirements
• Cost-effective access to U.S. capital markets through OTCQX platform

Negative

• Delisting from NASDAQ to OTCQX represents a downgrade in trading venue
• Potential reduction in trading liquidity and institutional investor access
• May face challenges in maintaining analyst coverage and market visibility

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Vaxart, Inc. previously traded on NASDAQ.

Vaxart, Inc. begins trading today on OTCQX under the symbol “VXRT.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

“We thank OTC Markets Group for welcoming us and appreciate our investors for their continued support” said Steven Lo, Vaxart CEO. “We remain focused on making meaningful scientific progress in developing oral pill vaccines to potentially transform public health.”

About Vaxart, Inc.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™️ Basic Market and Pink Limited Market.

Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit
www.otcmarkets.com.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

FAQ

Why did Vaxart (VXRT) move from NASDAQ to OTCQX in July 2025?

Vaxart transitioned from NASDAQ to trade on the OTCQX Best Market, which offers more cost-effective access to U.S. capital markets while maintaining high financial standards and corporate governance requirements.

What are the implications of Vaxart (VXRT) trading on OTCQX instead of NASDAQ?

Trading on OTCQX means lower costs and complexity for Vaxart, but may result in reduced trading liquidity and institutional investor access compared to NASDAQ listing.

What is Vaxart's (VXRT) current business focus after moving to OTCQX?

Vaxart remains focused on developing oral pill vaccines as a clinical-stage biotechnology company, aiming to transform public health.

How can investors access Vaxart (VXRT) stock information on OTCQX?

Investors can find Vaxart's financial disclosure and Real-Time Level 2 quotes on www.otcmarkets.com under the symbol VXRT.

What requirements did Vaxart (VXRT) meet to qualify for OTCQX trading?

To qualify for OTCQX, Vaxart had to meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.